Skip to Content

Merck KGaA MRK Stock Quote

| Rating as of

XETR:MRK

Morningstar‘s Stock Analysis MRK

Valuation
Currency in EUR
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Merck KGaA Turns in Solid Third Quarter; Raising FVE on Recent Cash Flows

Julie Utterback, CFA Senior Equity Analyst

Analyst Note

| Julie Utterback, CFA |

Narrow-moat Merck KGaA delivered third-quarter results that were about as expected, and the company continues to track toward our expectations for the full year. After recognizing cash flows generated since our last valuation update, we are raising our fair value estimate moderately. Shares recently traded slightly above our new fair value estimate.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics MRK

Company Profile MRK

Business Description

Merck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (46% of 2021 sales) provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (36%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (18%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.

Contact
Frankfurter Strasse 250
Darmstadt, HE, 64293, Germany
T +49 6151720
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Sep 30, 2022
Fiscal Year End Dec 31, 2022
Employees 63,723